Business
Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference
UPDATE: Fireside chat will be held on Tuesday, April 12, 2022, from 10:15 a.m. to 10:55 a.m. EDT NEW HAVEN, Conn., April 11, 2022 /PRNewswire/ -- Trevi
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"UPDATE: Fireside chat will be held on Tuesday, April 12, 2022, from 10:15 a.m. to 10:55 a.m. EDT\nNEW HAVEN, Conn., April 11, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced an updated time slot for their fireside chat at the 21st Annual Needham Virtual Healthcare Conference. Jennifer Good, President and Chief Executive Officer, along with Dr. Bill Forbes, Chief Development Officer, will participate in a fireside chat on Tuesday, April 12, 2022, at 10:15 a.m. ET.\n\n \n \n \n \n \n \n\n \nTrevi Therapeutics' fireside chat at Needham Virtual Healthcare Conference taking place April 12 at 10:15 am ETA live webcast of the fireside chat will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.\nAbout CANALInterim analysis results from the Phase 2 Cough And NALbuphine (CANAL) trial were statistically significant on the primary efficacy endpoint with a 77% reduction in daytime cough frequency from study baseline for Haduvio, demonstrating a 52% placebo-adjusted reduction in the geometric mean percent change (p","length":2855,"tagName":"div"}]